Objective: To identify the clinical and adverse effects of intravenous chemotherapy combined
with intraperitoneal chemotherapy in the treatment of gastric cancer with abdominal peritoneal
Methods: Retrospective analysis was performed on 49 gastric cancer patients with abdominal peritoneal
carcinomatosis. Patients were divided into two groups: patients subjected to intravenous chemotherapy
(n = 27) were defined as the Control group and patients subjected to combined intravenous and
intraperitoneal chemotherapy (n = 22) were defined as the Combination Therapy group. Then the objective
efficacy, survival, and adverse effects of two groups were evaluated.
Results: The clinical characteristics of two groups were equally distributed. Compared with the Control
group, the Objective Response Rate (ORR) and Disease Control Rate (DCR) of the Combination
Therapy group were significantly higher (all P<0.05). The Median Survival Time (MST) of the Control
group was (6.57 ± 0.75) months, which was significantly shorter than in the Combination Therapy
group (15.03 ± 2.31) months (P < 0.05). In addition, the 12-, 18-, 24-, 30-, 36-, and 60-month survival
rates of the Control group were all significantly lower than those of the Combination Therapy group.
Furthermore, the incidence of adverse reactions in the two groups was not statistically significant; neither
of the treatments resulted in severe complications.
Conclusion: Compared with intravenous chemotherapy alone, the combined intravenous and intraperitoneal
chemotherapy was more effective in improving quality of life and extending survival time in patients
with abdominal peritoneal carcinomatosis from gastric cancer. In addition, the combination
treatment is tolerable and therefore worth further clinical study.